

SARS-COV-2 NSP7&NSP8 Protein

Cat. No. NSP-VE178

Description

Source	SARS-COV-2 NSP7&NSP8 Protein is expressed from E.coil with His tag at the C-Terminus. It contains Ser1-Gln83(NSP7)&Ala1-Gln198(NSP8).
Accession	YP_009725303.1(NSP7)&YP_009725304.1(NSP8)
Molecular Weight	The protein has a predicted MW of 32.8 kDa same as Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE

Formulation and Storage

Formulation	Lyophilized from 0.22µm filtered solution in 20mM Tris, 150mM NaCl, 200mM Arginine (pH 8.2). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The crystal structure of the metabolite of remdesivir (Monophosphate of GS-441524) and NSP12-NSP8-NSP7 of SARS CoV-2 virus was recently reported. The crystal structures of ADP-Ribose or AMP and NSP3 of SARS CoV-2 virus were also released, recently. The crystal structure of NSP3 of SARS CoV-2 virus as an alternative binding site of AMP or ADP-ribose to treat COVID-19.

Assay Data

Tris-Bis PAGE



SARS-COV-2 NSP7&NSP8 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.